表紙
市場調査レポート

男性不妊症:パイプライン製品の分析

Male Infertility - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 255962
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
男性不妊症:パイプライン製品の分析 Male Infertility - Pipeline Review, H2 2015
出版日: 2015年08月19日 ページ情報: 英文 44 Pages
概要

男性不妊症とは、繁殖可能な女性を妊娠させる能力が男性側にない状態のことを指します。男性不妊症は造精機能障害や精子無力症、射精障害などが原因で発症します。主な症状として、睾丸周辺の痛みや腫れ、しこりなどが挙げられます。主な疾患素質として、喫煙や飲酒、体重超過、毒素への曝露、特定の疾患(腫瘍・慢性病ほか)などが考えられています。主な治療法には、外科手術やホルモン補充治療などがあります。

当レポートでは、世界各国での男性不妊症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

男性不妊症の概要

治療薬の開発

  • 男性不妊症向けパイプライン製品:概要
  • 男性不妊症向けパイプライン製品:比較分析

各企業で開発中の男性不妊症治療薬

大学/研究機関で研究中の男性不妊症治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

男性不妊症治療薬:開発中の製品の一覧(企業別)

男性不妊症治療薬:研究中の製品の一覧(大学/研究機関別)

男性不妊症治療薬の開発に従事している企業

  • Zydus Cadila Healthcare Limited
  • Access Pharmaceuticals, Inc.
  • Pantarhei Bioscience BV

男性不妊症:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • オキシトシン+エストロゲン
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • イソトレチノイン
  • 急性心筋梗塞・不妊症向けバイオシミラー(4)
  • 経口妊娠促進薬
  • 不妊症向けFSH作動薬
  • 不妊症向けバイオシミラー(6)
  • 不妊症向けバイオシミラー(5)
  • 不妊症向けバイオシミラー(7)
  • 男性不妊症向け幹細胞治療

男性不妊症治療薬:開発が休止状態の製品

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7009IDB

Summary

Global Markets Direct's, 'Male Infertility - Pipeline Review, H2 2015', provides an overview of the Male Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Male Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Male Infertility
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Male Infertility and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Male Infertility pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Male Infertility
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Male Infertility pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Male Infertility Overview
  • Therapeutics Development
    • Pipeline Products for Male Infertility - Overview
    • Pipeline Products for Male Infertility - Comparative Analysis
  • Male Infertility - Therapeutics under Development by Companies
  • Male Infertility - Therapeutics under Investigation by Universities/Institutes
  • Male Infertility - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Male Infertility - Products under Development by Companies
  • Male Infertility - Products under Investigation by Universities/Institutes
  • Male Infertility - Companies Involved in Therapeutics Development
    • AlphaMab Co., Ltd
    • Ferring International Center S.A.
    • Pantarhei Bioscience BV
    • PharmaEssentia Corporation
    • Zydus Cadila Healthcare Limited
  • Male Infertility - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (oxytocin + estrogen) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 5 for Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 6 for Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 7 for Infertility and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FE-999310 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LM-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LM-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCS-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-FSH - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize FSHR for Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trequinsin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Male Infertility - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Male Infertility, H2 2015
  • Number of Products under Development for Male Infertility - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Male Infertility - Pipeline by AlphaMab Co., Ltd, H2 2015
  • Male Infertility - Pipeline by Ferring International Center S.A., H2 2015
  • Male Infertility - Pipeline by Pantarhei Bioscience BV, H2 2015
  • Male Infertility - Pipeline by PharmaEssentia Corporation, H2 2015
  • Male Infertility - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Male Infertility - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Male Infertility, H2 2015
  • Number of Products under Development for Male Infertility - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top